Skip to content

The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis

The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis: Modern Diagnostic and Therapeutic Concepts

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05791357
Enrollment
100
Registered
2023-03-30
Start date
2020-04-01
Completion date
2024-10-31
Last updated
2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocarditis Infective

Brief summary

The aim of this study is to prospectively investigate the additional diagnostic value of broad range PCR targeting the 16 ribosomal DNA in diagnosis and management of patients with infective endocarditis who are candidate for surgicaltherapy;

Detailed description

Study protocol is divided into four different phases:screening, pre-operative clinical assessment (T-1), cardiac surgery (T0) and follow-up period (T4 eT90). During the screening phase, patients will be assessed to determine whether they met the study inclusion/exclusion criteria. After signing the informed consent, patients will go through a preoperative clinical evaluation (T-1). The following assessments are carried out the day before surgery: recording patient's generality, present antibiotic therapy and possible results of blood cultures performed prior to recruitment; - Twelve-lead ECG; - chest X-ray - transthoracic echocardiogram (TTE); -. three pairs of blood cultures from three different blood sampling sites. In cases of complicated endocarditis, the presence and location of septic embolisms is recorded (using Total body CT scan imaging), signs of heart failure evaluated and operability criteria are assessed. On the day of cardiac surgery (T0), main intraoperative data (valve findings, type of prosthesis, surgery time, cardiopulmonary bypass time and aortic cross clamping time) will be gathered; the excised valve was sent partly to the microbiology laboratory for culture and molecular tests and partly to the pathology Laboratory. After cardiac surgery, patients continued to be monitored for a follow up at four (T4) and 90 (T90) days after surgery. During the follow-up period, information was collected on the patient's clinical status (vital parameters) and the antibiotic treatment performed. The same blood tests performed at T-1 are repeated at T4 and T90. All this data was recorded on a dedicated database.

Interventions

DIAGNOSTIC_TESTPCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA

Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patients older than 18 years, with diagnosis of IE on a native or prosthetic valve and with a surgical indication for heart valve replacement using extracorporeal circulation (CPB). 2. patients who have signed informed consent to the partecipation of the study

Exclusion criteria

1. patients younger than 18 years 2. Failure to sign consent for personal data processing and/or study participation 3. Participation in other experimental studies 4. Patients who did not complete the examinations under study (culture test on blood and excised valve, molecular tests)

Design outcomes

Primary

MeasureTime frameDescription
Impact of molecular diagnostic tests on the identification of microorganismsthrough study completion, an average of 1 yearnumber of patients with positive blood cultures vs number of patients with negative blood cultures but with positive molecular diagnostic tests
number of microorganism isolatedthrough study completion, an average of 1 yearnumber of microorganism isolated through molecular diagnostic tests

Secondary

MeasureTime frameDescription
Impact of molecular diagnostic tests on antibiotic therapythrough study completion, an average of 1 yearNumber of patients with IE in which antibiotic therapy change because of the results of molecular diagnostic tests

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026